Dave Amerson

Serial Entrepreneur/Investor, Various Boards

David R. Amerson, former President and Chief Executive Officer of Neotract. He guided NeoTract through FDA-Approval, Reimbursement and Commercial Acceleration. The company was successfully acquired by Teleflex in 2017 for $1.1 billion. Mr. Amerson’s current board experience includes ProVerum Medical, MoxiMed Medical, Intrinsic Therapeutics, Calyxo Medical, Amber Therapeutics, and The Urology Care Foundation. Additionally, he has had significant involvement in over $3.2 billion in medical device transactions, including Palette Life Sciences and Relievant Medical.

Rob Hanson

EVP and General Management, Urology, Laborie

Rob Hanson is the Executive Vice President and General Manager for the global urology business at Laborie Medical Technologies. Laborie is focused on urology diagnostics and therapies, inclusive of urodynamics, cystoscopy, bladder ultrasound, overactive bladder, urethral stricture, and BPH. Laborie is owned by Patricia Industries, a division of the investment company Investor AB.

Rob spent most of his medical device career at C.R. Bard. He held multiple roles over 24 years, including global leadership of the urology business. Bard's business was focused on urological drainage products, endourology, surgical incontinence/prolapse, and prostate cancer. After the acquisition of Bard by Becton Dickinson, Rob held enterprise-level leadership roles across BD's 10 global business units.

Murielle Thinard McLane

Managing Partner & President, Intuitive Ventures

Murielle is Managing Partner and President of Intuitive Ventures, where she leads investment strategy focused on leaders shaping the future of patient care. With over 30 years of experience as a public company executive, entrepreneur, and investor across healthcare, she brings a unique perspective on companies delivering both clinical impact and financial returns.

Most recently, she served as CEO of Ontera and co-founded Nooma. As EIR at GE Ventures, she helped found Verana Health. She previously held GM roles at McKesson, overseeing multi-billion dollar P&Ls, and held strategic and operational roles at Novartis, Genentech, and UnitedHealth Group, beginning her career on Wall Street.

A recipient of Doctors of the World's 2008 Health and Human Rights Leadership Award, Murielle holds an MBA from Wharton (Kaiser Scholar) and an MS in Finance from Université de Lyon.

She is a board observer of Apreo, Surge Therapeutics, Optellum, Neocis Medical, Capstan Medical, Amber Therapeutics, and Dragon Vascular.

Jaideep (Jai) Rajput

Corporate Development Manager, Cook Medical

Jaideep Rajput is a Corporate Development and strategic investment leader in the medical device industry with deep expertise in urology and surgical innovation. He focuses on identifying and executing investments that align emerging technologies with long-term portfolio strategy. His experience spans minority growth investments, structured financings, distribution partnerships, and acquisition pathways designed to create both strategic and financial value. With a background in engineering, finance, and IP strategy, Jaideep evaluates opportunities through a lens of clinical impact, reimbursement durability, and scalable commercialization. He is passionate about helping founders navigate the intersection of capital, strategy, and operational execution.

Craig Smith, JD, BS

Senior Director, Venture Capital, Boston Scientific

Craig Smith is a Corporate Venture Capital professional at Boston Scientific. He sources, structures, negotiates, executes, and manages venture investments to maximize strategic interests and financial returns for BSC. He works closely with divisional and corporate subject matter experts as well as divisional Business Development leadership to ensure investments are investment grade and a divisional strategic fit. After several years at a large Boston law firm focusing on M&A, VC, capital markets, and corporate and SEC compliance, he moved to the BSC in-house legal department covering divisional and corporate matters with a focus on M&A and VC. Over three years ago, Craig moved into the corporate venture capital role within the business development function.